Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Malignant Melanoma

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 21 articles: HTML format

Single Articles

November 2025
1. SKARIN NORDENVALL A, Persson F, Martling A, Nordenskjold M, et al
   Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dube syndrome - a matched cohort study.
   Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03258.
   PubMed     Abstract available
   
   
   September 2025
2. VAN DAM S, Krijgsman D, Kucukkose E, Verdonschot MEL, et al
   Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.
   Br J Cancer. 2025 Sep 2. doi: 10.1038/s41416-025-03137.
   PubMed     Abstract available
   
   
   July 2025
3. SIMBA H, McCormack V, Bilaba J, Mmbaga BT, et al
   Non-melanoma skin cancer and HPV in persons with albinism: a call for research investment.
   Br J Cancer. 2025 Jul 4. doi: 10.1038/s41416-025-03107.
   PubMed     Abstract available
   
   
   May 2025
4. NORINGRIIS IM, Donia M, Madsen K, Schmidt H, et al
   Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.
   Br J Cancer. 2025 May 26. doi: 10.1038/s41416-025-03048.
   PubMed     Abstract available
   
   
   April 2025
5. VAN DIJK EJ, Nienhuis HH, van den Eertwegh AJM, Boers-Sonderen MJ, et al
   Rechallenge of ipilimumab and nivolumab in advanced melanoma patients after previous ipilimumab-based therapy.
   Br J Cancer. 2025 Apr 29. doi: 10.1038/s41416-025-03027.
   PubMed     Abstract available
   
   
   
6. BROCHE C, Um K, Vilgrain I, Mouret S, et al
   Soluble VE-cadherin as a biomarker of response to immunotherapy by anti-PD1 in metastatic melanoma.
   Br J Cancer. 2025 Apr 18. doi: 10.1038/s41416-025-03026.
   PubMed    
   
   
   
7. BLOEM M, de Meza MM, van den Eertwegh AJM, Aarts MJB, et al
   Adjuvant BRAF/MEK versus anti-PD-1 in BRAF-mutant melanoma: a propensity score matched survival analysis.
   Br J Cancer. 2025 Apr 15. doi: 10.1038/s41416-025-03021.
   PubMed     Abstract available
   
   
   November 2024
8. MHAIDAT NM, Zhang XD, Allen J, Avery-Kiejda KA, et al
   Editorial Expression of Concern: Temozolomide induces senescence but not apoptosis in human melanoma cells.
   Br J Cancer. 2024 Nov 18. doi: 10.1038/s41416-024-02907.
   PubMed    
   
   
   October 2024
9. CHATTOPADHYAY C, Roszik J, Bhattacharya R, Alauddin M, et al
   Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma.
   Br J Cancer. 2024 Oct 11. doi: 10.1038/s41416-024-02866.
   PubMed     Abstract available
   
   
   
10. PUDJIHARTONO M, Pudjihartono N, O'Sullivan JM, Schierding W, et al
    Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes.
    Br J Cancer. 2024 Oct 4. doi: 10.1038/s41416-024-02870.
    PubMed     Abstract available
    
    
    August 2024
11. ORAIOPOULOU ME, Couturier DL, Bunce EV, Cannell IG, et al
    The in vitro dynamics of pseudo-vascular network formation.
    Br J Cancer. 2024;131:457-467.
    PubMed     Abstract available
    
    
    
12. MERRICK S, Rush HL, Daniels S, Fielding A, et al
    Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition.
    Br J Cancer. 2024;131:515-523.
    PubMed     Abstract available
    
    
    June 2024
13. SCHORGHOFER D, Vock L, Mirea MA, Eckel O, et al
    Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation.
    Br J Cancer. 2024 Jun 20. doi: 10.1038/s41416-024-02758.
    PubMed     Abstract available
    
    
    February 2024
14. ZAKKAK N, Barclay ME, Swann R, McPhail S, et al
    The presenting symptom signatures of incident cancer: evidence from the English 2018 National Cancer Diagnosis Audit.
    Br J Cancer. 2024;130:297-307.
    PubMed     Abstract available
    
    
    December 2023
15. WANG S, Riedstra CP, Zhang Y, Anandh S, et al
    PTEN-restoration abrogates brain colonisation and perivascular niche invasion by melanoma cells.
    Br J Cancer. 2023 Dec 26. doi: 10.1038/s41416-023-02530.
    PubMed     Abstract available
    
    
    
16. MAVOR ME, Hanna TP, Asai Y, Langley H, et al
    Factors associated with the melanoma diagnostic interval in Ontario, Canada: a population-based study.
    Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02518.
    PubMed     Abstract available
    
    
    October 2023
17. LIU M, Dong Q, Chen B, Liu K, et al
    Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.
    Br J Cancer. 2023;129:1339-1349.
    PubMed     Abstract available
    
    
    
18. DONINI C, Galvagno F, Rotolo R, Massa A, et al
    PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade.
    Br J Cancer. 2023;129:1409-1416.
    PubMed     Abstract available
    
    
    July 2023
19. MARIANI P, Torossian N, van Laere S, Vermeulen P, et al
    Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
    Br J Cancer. 2023 Jul 13. doi: 10.1038/s41416-023-02331.
    PubMed     Abstract available
    
    
    March 2023
20. RODRIGUES A, Cosman R, Joshua AM
    Correction To: LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 28. doi: 10.1038/s41416-023-02231.
    PubMed    
    
    
    
21. RODRIGUES A, Cosman R, Joshua AM
    LXS196 for Metastatic Uveal Melanoma - finally some progress.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02199.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.